TIDMSN.

RNS Number : 1955P

Smith & Nephew Plc

20 June 2022

20 June 2022

Smith+Nephew announces new Senior Independent Director

Smith & Nephew plc (LSE:SN, NYSE:SNN) announces that Robin Freestone has decided to step down as Senior Independent Director and as a Non-Executive Director of Smith & Nephew plc with effect from 30 September 2022. Marc Owen, Non-Executive Director, will be appointed as Senior Independent Director with effect from the same date.

Mr Freestone was appointed as a Non-Executive Director in September 2015 and subsequently appointed as Senior Independent Director in April 2019. Mr Owen was appointed as a Non-Executive Director in October 2017. In addition to his appointment as Senior Independent Director, Mr Owen will continue in his role as Chair of the Compliance & Culture Committee and as a member of the Audit Committee and Nomination & Governance Committee. He will take over from Mr Freestone in leading the search for a new Chair of the company.

The Board would like to thank Mr Freestone for his commitment and contribution to the Board and the Company and to congratulate Mr Owen on his new appointment.

Enquiries

 
 
Investors 
Andrew Swift                       +44 (0) 1923 477433 
Smith+Nephew 
 
Media 
Charles Reynolds                   +44 (0) 1923 477314 
Smith+Nephew 
 
Susan Gilchrist / Ayesha Bharmal   +44 (0) 20 7404 5959 
Brunswick 
 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter , LinkedIn , Instagram or Facebook .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABSGDLSXBDGDL

(END) Dow Jones Newswires

June 20, 2022 02:00 ET (06:00 GMT)

Smith & Nephew (LSE:SN.)
Graphique Historique de l'Action
De Juil 2022 à Août 2022 Plus de graphiques de la Bourse Smith & Nephew
Smith & Nephew (LSE:SN.)
Graphique Historique de l'Action
De Août 2021 à Août 2022 Plus de graphiques de la Bourse Smith & Nephew